drugset
drugset / Trial / NCT03695198

A Study of LY3361237 in Healthy Participants

NCT03695198 ↗

Phase 1 Completed 64 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The purposes of this study are to determine: * The safety of LY3361237 and any side effects that might be associated with it. * How much LY3361237 gets into the blood stream and how long it takes the body to remove it in healthy participants. Participants will be admitted to the clinical research unit (CRU) for 4 overnight stays. The study will last about 12 weeks for each participant, not including screening.

Timeline

Start
2018-10-26
Primary completion
2019-08-29
Completion
2019-08-29

Drugs

EvaluationDrugModalityDoseRoute
Subject VENANPRUBART Monoclonal antibody — Subcutaneous

Indications

No indication recorded.